Prevention, even before birth. RSV vaccines in Denmark reduce hospital admissions

Since 1 October 2025, Copenhagen has been running a national vaccination campaign against respiratory syncytial virus (RSV) in pregnancy, significantly reducing the number of hospital admissions. Figures showing success

18 NOV 26
Translated by AI
Image of Prevention, even before birth. RSV vaccines in Denmark reduce hospital admissions

Photo: LaPresse

To protect children from respiratory syncytial virus (RSV), Denmark has taken action even before they are born. From 1 October 2025, Denmark launched a national vaccination campaign against RSV during pregnancy. The antibodies produced by the mother cross the placenta and protect the newborn during the first six months of life, the period when the risk of severe forms of the disease is highest. For high-risk babies, including premature infants whose mothers have not been vaccinated, monoclonal antibodies are administered instead. The result has been such a sharp decline that, according to Nature, those analysing the data began to wonder if there was an error: there were simply too few hospitalised babies. This is no trivial virus.
The World Health Organisation estimates that every year, RSV causes around 3.6 million hospitalisations and 100,000 deaths among children under the age of five. 97 per cent of these deaths occur in low- and middle-income countries. People over 60 with heart or respiratory conditions are also at risk. In the US, the CDC has estimated between 10,000 and 25,000 deaths over the last two winters. The news is that, after decades without specific preventive measures, the situation has now changed. Since 2022, nirsevimab, a long-acting monoclonal antibody, has been available in Europe; a second antibody and three vaccines for adults have also become available, one of which can also be used during pregnancy. Dozens of countries have already launched immunisation programmes. The Danish example shows how many hospitalisations can be avoided when prevention reaches those most at risk in good time. The burden of respiratory syncytial virus has long been underestimated, partly because it has rarely been screened for or diagnosed in adults. Today, we have tools to protect the most vulnerable people. The challenge – for our National Health Service too – is to ensure these reach those who need them most: every hospital admission prevented spares a person the consequences of a serious illness and frees up a bed for someone who needs it.